Should I buy or sell Personalis stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PSNL shares. View PSNL analyst ratings or view top-rated stocks .

What is Personalis' stock price target for 2024?

2 analysts have issued 1 year price objectives for Personalis' shares. Their PSNL share price targets range from $3.50 to $7.50. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 336.5% from the stock's current price. View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts .

How have PSNL shares performed in 2024?

Personalis' stock was trading at $2.10 at the beginning of the year. Since then, PSNL shares have decreased by 40.0% and is now trading at $1.26. View the best growth stocks for 2024 here .

When is Personalis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our PSNL earnings forecast .

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) posted its earnings results on Wednesday, February, 28th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The firm had revenue of $19.68 million for the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative trailing twelve-month return on equity of 61.42% and a negative net margin of 147.38%.

What ETF holds Personalis' stock?

ARK Genomic Revolution ETF holds 6,189,966 shares of PSNL stock, representing 0.56% of its portfolio.

What guidance has Personalis issued on next quarter's earnings?

Personalis issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.1 million.

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com . John West has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH) , Pfizer (PFE) , Dynavax Technologies (DVAX) , QUALCOMM (QCOM) , Advanced Micro Devices (AMD) , NIO (NIO) , NVIDIA (NVDA) , Viking Therapeutics (VKTX) , AbbVie (ABBV) and

When did Personalis IPO?

Personalis (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PSNL

Personalis (PSNL) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free PSNL Stock Alerts

$1.26

-0.01 (-0.79%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.24
▼
$1.32
50-Day Range: $1.15
▼
$1.75
52-Week Range: $0.89
▼
$3.14

Volume: 274,548 shs
Average Volume: 390,077 shs
Market Capitalization: $63.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Get Personalis alerts:

Personalis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 336.5% Upside
$5.50 Price Target
Short Interest: Healthy
2.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.62
Based on 4 Articles This Week
Insider Trading: Selling Shares
$1,702 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.58) to ($1.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.32 out of 5 stars

Medical Sector

125th out of 929 stocks

Medical Laboratories Industry

5th out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
Personalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Personalis has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.64% of the float of Personalis has been sold short.
Short Interest Ratio / Days to Cover
Personalis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Personalis has recently increased by 1.89%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Personalis does not currently pay a dividend.
Dividend Growth
Personalis does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Personalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.
Environmental Sustainability
The Environmental Impact score for Personalis is -0.66.

2.0

News and Social Media Coverage

News Sentiment
Personalis has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Personalis this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,702.00 in company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Personalis is held by insiders.
Percentage Held by Institutions
61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Personalis are expected to grow in the coming year, from ($1.58) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Personalis is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Personalis is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Personalis has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Personalis Stock (NASDAQ:PSNL)

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

PSNL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PSNL Stock News Headlines

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Personalis (NASDAQ:PSNL)

April 2, 2024 | investing.com

Cathie Wood's ARK makes major moves in Tesla stock, sells Robinhood

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

March 29, 2024 | investing.com

Cathie Wood's ARK buys over $14M in Tesla stock, sells Coinbase in latest trades

March 28, 2024 | businesswire.com

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 28, 2024 | businesswire.com

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 26, 2024 | finance.yahoo.com

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

March 19, 2024 | businesswire.com

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

March 16, 2024 | finance.yahoo.com

PSNL Apr 2024 2.500 put

March 6, 2024 | finance.yahoo.com

PSNL Apr 2024 7.500 call

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Personalis’s Strategic Advances and Financial Health Signal Promising Growth in 2024

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Personalis Amidst Strategic Partnerships and Revenue Growth Prospects

March 1, 2024 | seekingalpha.com

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

February 29, 2024 | uk.finance.yahoo.com

Personalis, Inc. (PSNL)

February 29, 2024 | finance.yahoo.com

Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript

February 28, 2024 | benzinga.com

Personalis: Q4 Earnings Insights

February 28, 2024 | finance.yahoo.com

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 | markets.businessinsider.com

What Wall Street expects from Personalis's earnings

February 14, 2024 | finance.yahoo.com

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024 | businesswire.com

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

January 31, 2024 | finance.yahoo.com

Personalis to Participate at Upcoming Investor Conferences

January 30, 2024 | markets.businessinsider.com

Personalis, ClearNote Health Join Hands To Advance Epigenomic Technology

January 30, 2024 | finance.yahoo.com

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

January 22, 2024 | finance.yahoo.com

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2024 | finance.yahoo.com

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

January 7, 2024 | uk.investing.com

Personalis reports 18% Q4 revenue growth, eyes 2026 runway

See More Headlines

Receive PSNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:PSNL
CUSIP: N/A
CIK: 1527753
Web: www.personalis.com
Phone: (650) 752-1300
Fax: N/A
Employees: 223
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $7.50
Low Stock Price Target: $3.50
Potential Upside/Downside: +336.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,300,000.00
Net Margins: -147.38%
Pretax Margin: -147.27%
Return on Equity: -61.42%
Return on Assets: -41.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.11
Quick Ratio: 2.88

Sales & Book Value

Annual Sales: $73.48 million
Price / Sales: 0.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.64 per share
Price / Book: 0.48

Miscellaneous

Outstanding Shares: 50,504,000
Free Float: 48,433,000
Market Cap: $63.64 million
Optionable: Optionable
Beta: 1.95

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Christopher M. Hall (Age 55)
President, CEO & Director
Comp: $963.75k
Mr. Aaron L. Tachibana (Age 63)
CFO & COO
Comp: $811k
Mr. Stephen M. Moore J.D. (Age 52)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $597.98k
Dr. Richard Chen M.D. (Age 53)
M.S., Executive VP of R&D and Chief Medical Officer
Comp: $800.6k
Dr. Russ B. Altman M.D.
Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Euan A. Ashley DPHIL (Age 53)
FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Michael P. Snyder Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board
Mr. Michael J Fitzpatrick
Vice President of Worldwide Sales
Dr. Christian Haudenschild Ph.D.
Senior Vice President of Genomic Laboratory Operations
Mr. Stephane Mouradian Ph.D.
Senior Vice President of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PSNL Stock Analysis - Frequently Asked Questions

Should I buy or sell Personalis stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PSNL shares.
View PSNL analyst ratings or view top-rated stocks.
What is Personalis' stock price target for 2024?: 2 analysts have issued 1 year price objectives for Personalis' shares. Their PSNL share price targets range from $3.50 to $7.50. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 336.5% from the stock's current price.
View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts.
How have PSNL shares performed in 2024?: Personalis' stock was trading at $2.10 at the beginning of the year. Since then, PSNL shares have decreased by 40.0% and is now trading at $1.26.
View the best growth stocks for 2024 here.
When is Personalis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PSNL earnings forecast.
How were Personalis' earnings last quarter?: Personalis, Inc. (NASDAQ:PSNL) posted its earnings results on Wednesday, February, 28th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The firm had revenue of $19.68 million for the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative trailing twelve-month return on equity of 61.42% and a negative net margin of 147.38%.
What ETF holds Personalis' stock?: ARK Genomic Revolution ETF holds 6,189,966 shares of PSNL stock, representing 0.56% of its portfolio.

What guidance has Personalis issued on next quarter's earnings?: Personalis issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.1 million.
What is John West's approval rating as Personalis' CEO?: 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees.
What other stocks do shareholders of Personalis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and
When did Personalis IPO?: Personalis (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Personalis?: Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSNL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Personalis (PSNL) Stock Price, News & Analysis

Personalis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Personalis Stock (NASDAQ:PSNL)

PSNL Stock Price History

PSNL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PSNL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™